Exploring the role of m7G modification in Cancer: Mechanisms, regulatory proteins, and biomarker potential.

The dysregulation of N(7)-methylguanosine (m7G) modification is increasingly recognized as a key factor in the pathogenesis of cancers. Aberrant expression of these regulatory proteins in various cancers, including lung, liver, and bladder cancers, suggests a universal role in tumorigenesis. Studies have established a strong correlation between the expression levels of m7G regulatory proteins, such as Methyltransferase like 1 (METTL1) and WD repeat domain 4 (WDR4), and clinical parameters including tumor stage, grade, and patient prognosis.

Impact of donor diabetes mellitus status on liver transplant outcomes in patients with acute-on-chronic liver failure.

Background: Liver transplantation (LT) is the most effective way to save patients with acute-on-chronic liver failure (ACLF). However, the impact of donor diabetes mellitus (DM) on LT outcomes in patients with ACLF has not been fully investigated.

Research Design And Methods: We retrospectively analyzed data from the Scientific Registry of Transplant Recipients (SRTR) between January 1, 2008 to December 31, 2017 in this study.

The interaction of T2DM and BMI with NASH in recipients of liver transplants: an SRTR database analysis.

Background: NASH-related liver transplants are increasing because of the obesity epidemic, but the influence of T2DM on various levels of BMI among NASH recipients is unclear.

Research Design And Methods: We analyzed data retrieved from SRTR on 4,515 patients. We divided patients by BMI into five groups: normal weight; overweight; class 1 obesity; class 2 obesity; and class 3 obesity.

The Prognostic Impact of Body Mass Index in Patients with Diffuse Large B-Cell Lymphoma: A Meta-Analysis.

Objective: Some studies on the relation between body mass index (BMI) and outcome of diffuse large B-cell lymphoma (DLBCL) remain controversial. We performed a meta-analysis to evaluate the overall survival (OS) and progression-free survival (PFS) of DLBCL in overweight (≥25 to <30 kg/m), obese (≥30 kg/m) and underweight (<18.5 kg/m) individuals compared with normal weight patients (≥18.